Ionizable Lipid — Proprietary Patented Structure
The core functional component of an LNP: a pH-responsive ionizable lipid with a proprietary, independently patented structure — not an SM-102 / ALC-0315 / MC3 analogue. China / US / EU patents; CDE excipient registration and FDA DMF filing completed. ISO 9001 / 13485, ICH-Q7A production.
Catalog no. IL-1G / IL-5G / IL-10G / IL-100G / IL-1KG · Ships with certificate of analysis
For Research Use OnlyOverview
Overview
The core functional component of a lipid nanoparticle. At acidic pH the lipid is protonated and positively charged, complexing and encapsulating negatively charged nucleic acids; at physiological pH it returns to near-neutral, reducing toxicity; after uptake it promotes endosomal escape — the step that determines delivery efficiency.
This material uses a proprietary, independently patented structure rather than a copy of foreign-patented lipids: no SM-102, ALC-0315 or MC3 exposure. Patents cover the full chain — compound, composition, LNP, nucleic-acid drug and formulation use — in China, the US and Europe.
Key specifications
| Chemical name | ((2-(2-hydroxyethoxy)ethyl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate) |
|---|---|
| Molecular weight | 782.29 |
| Charge behaviour | pH-responsive — protonated at low pH, near-neutral at physiological pH |
| Role | nucleic-acid complexation and encapsulation; endosomal escape |
| Form | waxy / oily (solid at low temperature — temper before use per protocol) |
| Storage | −20 ± 5 °C, keep dry and sealed |
| Quality system | ISO 9001 / ISO 13485; manufactured under ICH-Q7A (FDA API GMP guidance) |
| Regulatory filings | China CDE pharmaceutical excipient registration and US FDA DMF — completed |
| Patent coverage | proprietary structure; China, US and EU filings |
| Intended use | For Research Use Only |
Pack sizes
| Size | Part number |
|---|---|
| 1 g | IL-1G |
| 5 g | IL-5G |
| 10 g | IL-10G |
| 100 g | IL-100G |
| 1 kg | IL-1KG |
Availability of individual sizes is confirmed at enquiry; custom synthesis available.
Key features
- Proprietary patented structure — not an SM-102 / ALC-0315 / MC3 analogue: no foreign compound-patent exposure in export markets or downstream commercialisation
- Tri-region patent coverage — compound through formulation-use claims, protection from research to commercial stage
- Dual regulatory filings — CDE excipient registration and FDA DMF both completed; customers can reference the filing in drug registration. Filing numbers are provided under confidentiality at enquiry
- pH-responsive performance — tight nucleic-acid complexation at low pH, near-neutral at physiological pH, strong endosomal escape
- Industrial-scale supply — ten-kilogram-per-batch capacity, consistent between batches, from 1 g research packs to kilogram-scale pilot quantities
- Complete quality system — ISO 9001 / ISO 13485, production organised under ICH-Q7A
Applications
mRNA vaccine and therapeutic formulation; siRNA and oligonucleotide drug delivery; CRISPR and gene-editing delivery; inhaled-route LNPs (supported by published siRNA delivery literature); gram-scale research through kilogram-scale pilot supply, with custom structures on request.
Notes
- Cold-chain product — stored at −20 °C and shipped on dry ice; export packaging and transport conditions are confirmed at order. This is not an ambient reagent.
- For Research Use Only. Not a drug and not a diagnostic reagent; supplied exclusively for research applications. GMP-grade material with the full regulatory dossier for drug programmes is quoted separately, by grade, at enquiry.
- Patent numbers, filing numbers and batch documentation are provided one-to-one at enquiry.
- Pack sizes, COA, MSDS, ISO certificates, FOB pricing, MOQ and lead time confirmed at enquiry.
| Product | Ionizable Lipid — Proprietary Patented Structure |
|---|---|
| Catalog no. | IL-1G / IL-5G / IL-10G / IL-100G / IL-1KG |
| Category | Lipids & Materials |
| Documentation | Certificate of analysis provided with every lot |
| Intended use | For Research Use Only (RUO). Not for diagnostic or therapeutic use. |
Related products
Ionizable Lipid — ALC-0315 Type (Research Grade)
Research-grade ionizable lipid of the ALC-0315 type — the second-generation structure used in the Pfizer–BioNTech COVID-19 vaccine and the reference formulation for a large share of published LNP research. pH-responsive, ≥98% purity, −20 °C cold chain. Research use only.
Ionizable Lipid — MC3 Type (D-Lin-MC3-DMA, Research Grade)
Research-grade ionizable lipid of the MC3 (D-Lin-MC3-DMA) type — the first-generation benchmark lipid of Onpattro, the first approved siRNA drug. pKa ≈ 6.44, ≥98% purity, −20 °C cold chain. Research use only.
Vaccinia Capping Enzyme (mRNA 5' Capping, Cap 0/Cap 1)
Recombinant vaccinia capping enzyme (D1-D12) with three-in-one activity for enzymatic mRNA 5' capping — ~100% Cap 0 in 1 hour, upgradeable to Cap 1. Low endotoxin, low host residuals, RUO.
Get a quote for Ionizable Lipid — Proprietary Patented Structure
Specs, pricing, lead time and shipping options — usually within one business day.